Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

Kala-Azar Research Centre Muzaffarpur, Brahmpura, Muzaffarpur, Bihar, India.
BMJ Clinical Research (Impact Factor: 14.09). 05/1998; 316(7139):1200-5.
Source: PubMed


To assess the efficacy and tolerability of aminosidine compared with sodium stibogluconate for treating visceral leishmaniasis.
Randomised, unblinded, controlled trial with 180 day follow up.
Kala-Azar Research Centre, Brahmpura, Muzaffarpur, Bihar, India.
People of either sex aged 6-50 years with symptoms and signs suggestive of visceral leishmaniasis (fever, loss of appetite, enlarged spleen) with leishmania amastigotes detected in Giemsa stained aspirates of spleen or bone marrow.
Aminosidine at three daily doses (12, 16, and 20 mg/kg) for 21 days and sodium stibogluconate 20 mg/kg/day for 30 days.
Laboratory measures of efficacy: parasite count, haemoglobin concentration, white cell count, platelet count, serum albumin concentration. Clinical measures of efficacy: spleen size, fever, body weight, and liver size. Measures of safety: liver and renal function tests, reports of adverse events.
Of the 120 patients enrolled (30 per treatment arm), 119 completed treatment and follow up. Cure at end of follow up was achieved in 23 (77%), 28 (93%), and 29 (97%) patients treated with 12, 16, and 20 mg aminosidine/kg/day respectively, and in 19 (63%) patients given sodium stibogluconate. At 16 and 20 mg/kg/day, aminosidine was significantly more active than sodium stibogluconate in both clinical and laboratory measures of efficacy. No significant clinical or laboratory toxicity occurred in any treatment group.
A 21 day course of aminosidine 16 or 20 mg/kg/day should be considered as first line treatment for visceral leishmaniasis in Bihar.

Full-text preview

Available from:
  • Source
    • "In 2002, it was first introduced as anti-leishmanial drug in the form of PM sulphate.[22] Low cost, fewer side-effects, better efficacy and shorter duration of administration make this drug popular and thought to be a candidate for the first line therapy for VL patients.[23242526] It belongs to the aminoglycoside group of antibiotic; hence, the mechanism of action is by inhibition of protein synthesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Leishmaniasis is a vector borne protozoan disease and it remains a major public health problem world-wide. Lack of an effective vaccine and vector control program makes the chemotherapy as the primary tool for leishmaniasis. Antimonials were used as the first line of treatment for many years. Emergence of resistance against this drug has become a major concern. Literatures and studies published on anti-leishmanial drug resistance, newer drug discovery for leishmanial resistance etc., in PubMed, Medline and Google search and reviewed thoroughly. Various newer drugs have been identified but, are in limited use because of high cost, toxicity, resistance etc., Recently, many newer mechanisms of drug resistance have been identified which may boost in future designing and development of drugs.
    Full-text · Article · Mar 2014
  • Source
    • "In addition to this, paromomycin showed a lower incidence of side effects, which included ototoxicity and renal toxicity. For this reason, it was concluded from this study that paromomycin was an adequate second-line treatment in cases resistant to antimonials [88]. These results led to the development of a phase III trial in Bihar from 2003 to 2004, where paromomycin was not inferior to amphotericin B deoxycholate, with final cure rates of 94.6 versus 98.8 %, respectively [89]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection, malnourishment and other concomitant infections. This article provides an exhaustive review of the literature regarding studies published on the treatment of VL, and gives therapeutic recommendations stratified according to their level of evidence, the species of Leishmania implicated and the geographical location of the infection.
    Full-text · Article · Oct 2013 · Drugs
  • Source
    • "This alarming situation intensified research into the mechanisms by which Leishmania acquires resistance to drugs. Drug resistance in this organism (but also in Plasmodium and Entamoeba parasites as well as in neoplastic cells) is associated with a multidrug-resistant (MDR) phenotype characterized by the over-expression of a P-glycoprotein, Pgp 170 (130 to 200 kDa) [7], [8], [9]. It acts as a transmembrane efflux pump for a diverse group of lipophilic compounds, including many chemically diverse drugs and fluorescent dyes as well as calcium channel blockers [10], [11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Resistance of pathogens to drugs is a growing concern regarding many diseases. Parasites like Leishmania, Plasmodium and Entamoeba histolytica; and neoplastic cells, present the multidrug-resistant phenotype rendering chemotherapy ineffective. The acquired resistance of Leishmania to antimony has generated intense research on the mechanisms involved but the question has not yet been resolved. To test the hypothesis that drug efflux in Leishmania, as measured by flow cytometry using the fluorescent dye Rhodamine-123, is largely dependent on the number of efflux pumps an isolate can express, the amount of Pgp 170 molecules was assessed in ten field isolates (5 "resistant" and 5 "susceptible") using: Western Blotting, Confocal and Transmission Electron Microscopy, and proteomics. Their survival after exposure to three antileishmanial drugs, in vitro, was evaluated and clinical data were compared to the in vitro results. All isolates were resistant to Glucantime but susceptible to Miltefosine, whilst Amphotericin B was more effective on the "susceptible" isolates. The MDR gene, expressing the transmembrane efflux pump Pgp 170, appears to play a key role in the phenomenon of drug resistance. When "susceptible" versus "resistant" parasites were compared, it was shown that the higher the number of Pgp 170 molecules the higher the Rhodamine-123 efflux from the parasite body and, when exposed to the drug, the number of efflux pumps increased. However, the rate of this increase was not linear and it is possible that there is a maximum number of Pgp 170 molecules an isolate can express. Nevertheless, the phenomenon is a complex one and other factors and proteins are involved in which the HSP-70 group proteins, detected in the "resistant" isolates, may play a significant role.
    Full-text · Article · Jun 2013 · PLoS ONE
Show more